Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds
Open Access
- 12 February 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 8 (8), 1983-1996
- https://doi.org/10.1039/d0qi01344g
Abstract
Platinum-based therapies continue to be the main regimen used to treat non-small cell lung cancers (NSCLC), where multidrug resistance plays a key role in treatment failure and strategies to overcome this limitation are urgently sought for. In view to contribute to the development of this field, two sets of new organometallic Ru(II) compounds with general formula [Ru(η5-C5H4R′)(bipyR)(PPh3)][CF3SO3], where R′ = CHO or CH2OH and bipyR = 2,2′-bipyridine (1, 5), 4,4′-dimethyl-2,2′-bipyridine (2, 6), 4,4′-di(hydroxymethyl)-2,2′-bipyridine (3, 7) and 4,4′-dibiotin ester-2,2′-bipyridine (4), were synthesized and fully characterized. All compounds were tested against four types of NSCLC cell lines (A549, NCI-H228, Calu-3 and NCI-H1975), and four of them (1, 2, 4 and 6) presented a strong activity against cisplatin-resistant NSCLC cells. They were also able to increase cisplatin cytotoxicity up to 1390-fold (when administrated at nontoxic doses) by inhibiting MRP1 and P-gp transporters. Given the role of MRP1 in cisplatin resistance, in particular in lung cancer where cisplatin is the first-line treatment, the finding that these compounds are inducers of collateral sensitivity is of particular relevance. As far as we are aware, these are the first ruthenium-based compounds with such a mechanism of action, taking advantage of an “Achilles’ heel” and acting as MDR-selective compounds.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (CEECIND/01974/2017, PTDC/QUI-QIN/28662/2017, SFRH/BD/135830/2018, UIDB/00100/2020)
- Associazione Italiana per la Ricerca sul Cancro (IG21408)
- European Cooperation in Science and Technology (COST Action 17104 STRATAGEM)
This publication has 46 references indexed in Scilit:
- NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical applicationChemical Science, 2014
- Insights in the chemical components of liposomes responsible for P-glycoprotein inhibitionNanomedicine: Nanotechnology, Biology and Medicine, 2014
- The molecular interaction of a copper chelate with human P-glycoproteinMolecular and Cellular Biochemistry, 2012
- Conjugation of Organoruthenium(II) 3-(1H-Benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and Indolo[3,2-d]benzazepines to Recombinant Human Serum Albumin: a Strategy To Enhance Cytotoxicity in Cancer CellsInorganic Chemistry, 2011
- An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone)glycinate to overcome multidrug resistance in cancerDalton Transactions, 2011
- Targeting Mitochondrial Cell Death Pathway to Overcome Drug Resistance with a Newly Developed Iron ChelatePLOS ONE, 2010
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- A short history of SHELXActa Crystallographica Section A Foundations of Crystallography, 2007
- Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance MechanismsJournal of Medicinal Chemistry, 2007
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002